Abcam, ab249448, Anti-NEDD4-2 (phospho S448) antibody [EPR8269(2)] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal NEDD4-2 phospho S448 antibody. Carrier free. Suitable for IP, WB and reacts with Human samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR8269(2),
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:IP, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab249448 is the carrier-free version of
ab168349
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
NEDD4-2 also known as NEDD4L is a HECT domain-containing ubiquitin E3 ligase with a mass of approximately 120 kDa. It is expressed in various tissues especially in the kidney lung and colon. NEDD4-2 is involved in tagging proteins with ubiquitin marking them for degradation via the proteasome pathway. This protein helps regulate protein turnover by attaching ubiquitin chains to specific substrate proteins.
Biological function summary
NEDD4-2 regulates key cellular processes by controlling the abundance of membrane proteins like ion channels and receptors. It binds and ubiquitinates specific targets like ENaC (epithelial sodium channel) significantly influencing electrolyte and fluid balance. NEDD4-2 often functions as part of multiprotein complexes that modulate cellular homeostasis. Efficient function of these complexes ensures cells maintain balance in their environment.
Pathways
NEDD4-2 integrates into the MAPK and Wnt signaling pathways influencing diverse cellular outcomes like proliferation and apoptosis. Acting within these pathways NEDD4-2 associates with proteins such as Ras and β-catenin. This interaction influences cellular responses to external stimuli playing roles in cellular growth regulation and fate decisions.
Abnormalities in NEDD4-2 function are linked to conditions like Liddle's syndrome and hypertension. Mutations or dysregulation in NEDD4-2 can alter ENaC activity leading to increased sodium retention and contribute to high blood pressure. Moreover it connects to disorders like epithelial cancers through pathways involving β-catenin indicating its potential role in tumorigenesis. Research continues to explore these interactions to identify therapeutic targets.